Imaging & Biomarker Correlates on Outcomes in a Phase II Trial of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Radiotherapy (HIGRT) in Potentially Resectable Pancreas Cancer
Publication
, Conference
Kent, CL; Marin, D; Niedzwiecki, D; Stephens, SJ; Duffy, E; Malicki, M; Abbruzzese, J; Uronis, H; Blobe, G; Blazer, DG; Czito, B; Willett, CG ...
Published in: International Journal of Radiation Oncology*Biology*Physics
September 2019
Duke Scholars
Published In
International Journal of Radiation Oncology*Biology*Physics
DOI
ISSN
0360-3016
Publication Date
September 2019
Volume
105
Issue
1
Start / End Page
E238 / E239
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kent, C. L., Marin, D., Niedzwiecki, D., Stephens, S. J., Duffy, E., Malicki, M., … Palta, M. (2019). Imaging & Biomarker Correlates on Outcomes in a Phase II Trial of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Radiotherapy (HIGRT) in Potentially Resectable Pancreas Cancer. In International Journal of Radiation Oncology*Biology*Physics (Vol. 105, pp. E238–E239). Elsevier BV. https://doi.org/10.1016/j.ijrobp.2019.06.2014
Kent, C. L., D. Marin, D. Niedzwiecki, S. J. Stephens, E. Duffy, M. Malicki, J. Abbruzzese, et al. “Imaging & Biomarker Correlates on Outcomes in a Phase II Trial of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Radiotherapy (HIGRT) in Potentially Resectable Pancreas Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 105:E238–39. Elsevier BV, 2019. https://doi.org/10.1016/j.ijrobp.2019.06.2014.
Kent CL, Marin D, Niedzwiecki D, Stephens SJ, Duffy E, Malicki M, et al. Imaging & Biomarker Correlates on Outcomes in a Phase II Trial of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Radiotherapy (HIGRT) in Potentially Resectable Pancreas Cancer. In: International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2019. p. E238–9.
Kent, C. L., et al. “Imaging & Biomarker Correlates on Outcomes in a Phase II Trial of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Radiotherapy (HIGRT) in Potentially Resectable Pancreas Cancer.” International Journal of Radiation Oncology*Biology*Physics, vol. 105, no. 1, Elsevier BV, 2019, pp. E238–39. Crossref, doi:10.1016/j.ijrobp.2019.06.2014.
Kent CL, Marin D, Niedzwiecki D, Stephens SJ, Duffy E, Malicki M, Abbruzzese J, Uronis H, Blobe G, Blazer DG, Czito B, Willett CG, Palta M. Imaging & Biomarker Correlates on Outcomes in a Phase II Trial of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Radiotherapy (HIGRT) in Potentially Resectable Pancreas Cancer. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2019. p. E238–E239.
Published In
International Journal of Radiation Oncology*Biology*Physics
DOI
ISSN
0360-3016
Publication Date
September 2019
Volume
105
Issue
1
Start / End Page
E238 / E239
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences